Determining the Minimal Clinical Important Difference for Medication Quantification Scale III and Morphine Milligram Equivalents in Patients with Failed Back Surgery Syndrome
Lisa Goudman, Ann De Smedt, Patrice Forget, Maarten Moens, Lisa Goudman, Ann De Smedt, Patrice Forget, Maarten Moens
Abstract
The Medication Quantification Scale III (MQS) is a tool to represent the negative impact of medication. A reduction in medication can serve as an indicator to evaluate treatment success. However, no cut-off value has yet been determined to evaluate whether a decrease in medication is clinically relevant. Therefore, the objective is to estimate the thresholds for the MQS and morphine milligram equivalents (MMEs) that best identify a clinically relevant important improvement for patients. Data from the Discover registry, in which patients with failed back surgery syndrome were treated with high-dose spinal cord stimulation, were used. Patient satisfaction was utilized to evaluate a clinically important outcome 12 months after stimulation. Anchor-based and distribution-based methods were applied to determine the minimal clinical important difference (MCID). Distribution-based methods revealed a value of 4.28 for the MQS and 33.61 for the MME as MCID. Anchor-based methods indicated a percentage change score of 41.2% for the MQS and 28.2% for the MME or an absolute change score of 4.72 for the MQS and 22.65 for the MME. For assessing a treatment outcome, we recommend using the percentage change score, which better reflects a clinically important outcome and is not severely influenced by high medication intake at baseline.
Keywords: clinical importance; minimal clinically important difference; responsiveness.
Conflict of interest statement
Patrice Forget has been an advisory board member for Grunenthal. Maarten Moens has received speaker fees from Medtronic and Nevro. There are no other conflicts of interests to declare.
Figures
References
- Baber Z., Erdek M. Failed back surgery syndrome: Current perspectives. J. Pain Res. 2016;9:979–987. doi: 10.2147/JPR.S92776.
- Merskey H., Bogduk N. Classification of Chronic Pain. 2nd ed. IASP; Washington, DC, USA: 1994. Lumbar Spinal or Radicular Pain after Failed Spinal Surgery.
- Wille F., Breel J.S., Bakker E.W., Hollmann M.W. Altering Conventional to High Density Spinal Cord Stimulation: An Energy Dose-Response Relationship in Neuropathic Pain Therapy. Neuromodul. Technol. Neural Interface. 2016;20:71–80. doi: 10.1111/ner.12529.
- Pilitsis J., Fahey M., Custozzo A., Chakravarthy K., Capobianco R. Composite Score Is a Better Reflection of Patient Response to Chronic Pain Therapy Compared With Pain Intensity Alone. Neuromodul. Technol. Neural Interface. 2020 doi: 10.1111/ner.13212.
- Goudman L., De Smedt A., Eldabe S., Rigoard P., Linderoth B., De Jaeger M., Moens M. High-dose spinal cord stimulation for patients with failed back surgery syndrome. Pain. 2020 doi: 10.1097/j.pain.0000000000002035.
- Pope J.E., Fishman M. Redefining Success: Longitudinal Patient Reported Outcome Measures and the Importance of Psychometric Testing for Optimization in Neuromodulation. Neuromodul. Technol. Neural Interface. 2018;22 doi: 10.1111/ner.12907.
- Goudman L., Moens M. Moving Beyond a Pain Intensity Reporting: The Value of Goal Identification in Neuromodulation. Neuromodul. Technol. Neural Interface. 2020;23:1057–1058. doi: 10.1111/ner.13151.
- Goldsmith C.H., Boers M., Bombardier C., Tugwell P. Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J. Rheumatol. 1993;20:561–565.
- Wells G., Beaton D., Shea B., Boers M., Simon L., Strand V., Brooks P., Tugwell P. Minimal clinically important differences: Review of methods. J. Rheumatol. 2001;28:406–412.
- Daniell J.R., Osti O.L. Failed Back Surgery Syndrome: A Review Article. Asian Spine J. 2018;12:372–379. doi: 10.4184/asj.2018.12.2.372.
- Pollard E.M., Lamer T.J., Moeschler S.M., Gazelka H.M., Hooten W.M., Bendel M.A., Warner N.S., Murad M.H. The effect of spinal cord stimulation on pain medication reduction in intractable spine and limb pain: A systematic review of randomized controlled trials and meta-analysis. J. Pain Res. 2019;12:1311–1324. doi: 10.2147/JPR.S186662.
- Steedman S.M., Middaugh S.J., Kee W.G., Carson D.S., Harden R.N., Miller M.C. Chronic-pain medications: Equivalence levels and method of quantifying usage. Clin. J. Pain. 1992;8:204–214. doi: 10.1097/00002508-199209000-00004.
- Gallizzi M., Gagnon C., Harden N.R., Stanos S., Khan A. Medication Quantification Scale Version III: Internal Validation of Detriment Weights Using a Chronic Pain Population. Pain Pract. 2008;8:1–4. doi: 10.1111/j.1533-2500.2007.00163.x.
- De Jaeger M., Van Hooff R.-J., Goudman L., Espinoza A.V., Brouns R., Puylaert M., Duyvendak W., Moens M. High-Density in Spinal Cord stimulation: Virtual Expert Registry (DISCOVER): Study Protocol for a Prospective Observational Trial. Anesthesiol. Pain Med. 2017;7:e13640. doi: 10.5812/aapm.13640.
- Harden N.R., Weinland S.R., Remble T.A., Houle T.T., Colio S., Steedman S., Kee W.G. Medication Quantification Scale Version III: Update in Medication Classes and Revised Detriment Weights by Survey of American Pain Society Physicians. J. Pain. 2005;6:364–371. doi: 10.1016/j.jpain.2005.01.350.
- Centers for Disease Control and Prevention CDC Compilation of Benzodiazepines, Muscle Relaxants, Stimulants, Zolpidem, and Opioid Analgesics with Oral Morphine Milligram Equivalent Conversion Factors. [(accessed on 10 April 2020)];2017 Available online: .
- Austevoll I.M., Gjestad R., Grotle M., Solberg T., Brox J.I., Hermansen E., Rekeland F., Indrekvam K., Storheim K., Hellum C. Follow-up score, change score or percentage change score for determining clinical important outcome following surgery? An observational study from the Norwegian registry for Spine surgery evaluating patient reported outcome measures in lumbar spinal stenosis and lumbar degenerative spondylolisthesis. BMC Musculoskelet. Disord. 2019;20:1–15. doi: 10.1186/s12891-018-2386-y.
- Sedaghat A.R. Understanding the Minimal Clinically Important Difference (MCID) of Patient-Reported Outcome Measures. Otolaryngol. Neck Surg. 2019;161:551–560. doi: 10.1177/0194599819852604.
- Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin. Trials. 1989;10:407–415. doi: 10.1016/0197-2456(89)90005-6.
- Norman G.R., Sloan J.A., Wyrwich K.W. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med. Care. 2003;41:582–592. doi: 10.1097/01.MLR.0000062554.74615.4C.
- Copay A.G., Subach B.R., Glassman S.D., Polly D.W., Schuler T.C. Understanding the minimum clinically important difference: A review of concepts and methods. Spine J. 2007;7:541–546. doi: 10.1016/j.spinee.2007.01.008.
- Samsa G., Edelman D., Rothman M.L., Williams G.R., Lipscomb J., Matchar D. Determining Clinically Important Differences in Health Status Measures. PharmacoEconomics. 1999;15:141–155. doi: 10.2165/00019053-199915020-00003.
- Schwind J., Learman K., O’Halloran B., Showalter C., Cook C. Different minimally important clinical difference (MCID) scores lead to different clinical prediction rules for the Oswestry disability index for the same sample of patients. J. Man. Manip. Ther. 2013;21:71–78. doi: 10.1179/2042618613Y.0000000028.
- Voon P., Karamouzian M., Nguyen P. Chronic pain and opioid misuse: A review of reviews. Subst. Abus. Treat. Prev. Policy. 2017;12:1–9. doi: 10.1186/s13011-017-0120-7.
- Kalkman G.A., Kramers C., Van Dongen R.T., Brink W.V.D., Schellekens A. Trends in use and misuse of opioids in the Netherlands: A retrospective, multi-source database study. Lancet Public Health. 2019;4:e498–e505. doi: 10.1016/S2468-2667(19)30128-8.
- Dowell D., Haegerich T.M., Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. MMWR Recomm. Rep. 2016;65:1–49. doi: 10.15585/mmwr.rr6501e1.
- Dowell D., Haegerich T.M. Using the CDC Guideline and Tools for Opioid Prescribing in Patients with Chronic Pain. Am. Fam. Physician. 2016;93:970–972.
- Philpot L.M., Ramar P., Elrashidi M.Y., Mwangi R., North F., Ebbert J.O. Controlled Substance Agreements for Opioids in a Primary Care Practice. J. Pharm. Policy Pract. 2017;10:29. doi: 10.1186/s40545-017-0119-5.
- Stratford P.W., Binkley J.M., Riddle D.L., Guyatt G.H. Sensitivity to Change of the Roland-Morris Back Pain Questionnaire: Part 1. Phys. Ther. 1998;78:1186–1196. doi: 10.1093/ptj/78.11.1186.
- Riddle D.L., Stratford P.W., Binkley J.M. Sensitivity to Change of the Roland-Morris Back Pain Questionnaire: Part 2. Phys. Ther. 1998;78:1197–1207. doi: 10.1093/ptj/78.11.1197.
- Salaffi F., Stancati A., Silvestri C.A., Ciapetti A., Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur. J. Pain. 2004;8:283–291. doi: 10.1016/j.ejpain.2003.09.004.
- Wright A.A., Hannon J., Hegedus E.J., Kavchak A.E. Clinimetrics corner: A closer look at the minimal clinically important difference (MCID) J. Man. Manip. Ther. 2012;20:160–166. doi: 10.1179/2042618612Y.0000000001.
- Wyrwich K.W., Tierney W.M., Wolinsky F.D. Further Evidence Supporting an SEM-Based Criterion for Identifying Meaningful Intra-Individual Changes in Health-Related Quality of Life. J. Clin. Epidemiol. 1999;52:861–873. doi: 10.1016/S0895-4356(99)00071-2.
Source: PubMed